According to analysts, VYNE price target is USD with a max estimate of USD and a min estimate of USD. Check if this forecast comes true in a year. On average, analysts forecast that VYNE's EPS will be -$ for , with the lowest EPS forecast at -$, and the highest EPS forecast at -$ On. VYNE Therapeutics Stock Forecast, VYNE stock price prediction. Price target in 14 days: USD. The best long-term & short-term VYNE Therapeutics share. Track VYNE Therapeutics Inc (VYNE) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get. Get Vyne Therapeutics Inc (VYNE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.
VYNE Therapeutics Inc Price (VYNE) Daily Price Prediction Charts. VYNE Therapeutics (NASDAQ:VYNE) Stock, Analyst Ratings, Price Targets, Forecasts VYNE Therapeutics Inc has a consensus price target of $ based on the. VYNE Therapeutics Inc. ; Next Fiscal Year Estimate, ; Median PE on Next FY Estimate, N/A ; High, $ ; Median, $ ; Low, $ VYNE Therapeutics (VYNE) stock price prediction is 0 USD. The VYNE Therapeutics stock forecast is 0 USD for July 29, Tuesday with technical analysis. According to 1 stock analyst, the rating for VYNE is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near. VYNE's current price target is $ Learn why top analysts are making this stock forecast for VYNE Therapeutics at MarketBeat. View VYNE Therapeutics Inc VYNE stock quote prices, financial information, real-time forecasts, and company news from CNN. Key Stock Data · P/E Ratio (TTM). N/A · EPS (TTM). $ · Market Cap. $ M · Shares Outstanding. M · Public Float. M · Yield. VYNE is not. Based on analysts offering 12 month price targets for VYNE in the last 3 months. The average price target is $ with a high estimate of $6 and a low. Stocks. USA. The Naive Prediction forecasted value of Vyne Therapeutics on the next trading day is expected to be with a mean absolute deviation of.
VYNE Stock Overview · Revenue is forecast to grow % per year · Earnings have grown % per year over the past 5 years · Analysts in good agreement that. Find the latest VYNE Therapeutics Inc. (VYNE) stock quote, history, news and other vital information to help you with your stock trading and investing. Analyst Forecast. According to one analyst, the rating for VYNE stock is "Strong Buy" and the month stock price forecast is $ Like the earnings yield, which shows the anticipated yield (or return) on a stock based on the earnings and the price paid, the cash yield does the same, but. The average one-year price target for VYNE Therapeutics Inc. is $ The A stock's price target is the price at which analysts consider it fairly. Earnings for VYNE Therapeutics are expected to decrease in the coming year, from ($) to ($) per share. Price to Earnings Ratio vs. the Market. The P/E. The Vyne Therapeutics Inc stock price fell by % on the last day (Tuesday, 20th Aug ) from $ to $ During the last trading day the stock. The current price of VYNE is USD — it has decreased by −% in the past 24 hours. Watch VYNE Therapeutics Inc. stock price performance more closely on. VYNE Therapeutics (VYNE) has a Smart Score of 2 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund.
View VYNE Therapeutics Inc (VYNE) stock price today, market news, streaming charts, forecasts and financial information from FX Empire. Based on short-term price targets offered by three analysts, the average price target for VYNE Therapeutics Inc. comes to $ The forecasts range from a low. VYNE Therapeutics Forecast Revenue Growth Analysts estimate an earnings increase this quarter of $ per share, a decrease next quarter of $ per share. Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. Bid Price and Ask Price. The bid & ask refers to the price that an. Discover VYNE Therapeutics' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers.